<DOC>
	<DOCNO>NCT01237977</DOCNO>
	<brief_summary>The purpose study test hypothesis efficacy safety Meditoxin® inferior Botox® 's treatment glabellar line .</brief_summary>
	<brief_title>Efficacy Safety Study Botulinum Toxin Type A Treat Glabellar Lines</brief_title>
	<detailed_description>The allocated subject inject Investigational Product ( Meditoxin® Botox® ) 20U middle forehead . The efficacy safety evaluate 16weeks 4 follow visit .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Men woman age 20 65 Patients attain ≥grade 2 ( moderate ) investigator 's rating severity glabella line maximum frown Patients comply study procedure visit schedule Patients voluntarily sign informed consent Patients medical condition may great risk due administration investigational drug ( e.g.. disease may affect neuromuscular action include Myasthenia Gravis , LambertEaton Syndrome , Amyotrophic Lateral Sclerosis motor neuropathy ) Patients severe internal disease ( cardiovascular , respiratory , endocrine disease etc . ) Patients bleed tendency take anticoagulant Patients inject botulinum toxin within past 3 month Patients allergy hypersensitivity investigational drug component Female subject pregnant lactating . Female subject childbearing age plan get pregnant study period , use available contraceptive method ( Women childbearing age negative urine pregnancy test result baseline visit ( 0 week ) prior first injection . ) Patients history facial nerve paralysis symptom eyelid ptosis Patients skin disorder infection injection site Patients receive procedure may affect glabellar forehead line within 6 month Patients history treatment glabellar part ( include forehead ) like face lift permanent implant scar may affect treatment result Patients whose glabellar line satisfactorily improve physical method since line flatten even use hand Patients plan receive facial cosmetic procedure include dermal filler , photorejuvenation , chemical peel dermabrasion study period Patients participate clinical trial participate clinical trial 30 day screen five time half life drug give patient previous clinical trial Patients unable communicate follow instruction Patients eligible study base judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>